These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

243 related items for PubMed ID: 26531286

  • 21. Modeling of the impact on health outcomes of the use of dabigatran in patients with atrial fibrillation.
    Chevalier J, Giroud M, de Pouvourville G.
    Cerebrovasc Dis; 2013; 35(4):320-6. PubMed ID: 23615428
    [Abstract] [Full Text] [Related]

  • 22. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
    Maura G, Blotière PO, Bouillon K, Billionnet C, Ricordeau P, Alla F, Zureik M.
    Circulation; 2015 Sep 29; 132(13):1252-60. PubMed ID: 26199338
    [Abstract] [Full Text] [Related]

  • 23. Bleeding outcomes associated with rivaroxaban and dabigatran in patients treated for atrial fibrillation: a systematic review and meta-analysis.
    Bundhun PK, Soogund MZ, Teeluck AR, Pursun M, Bhurtu A, Huang WQ.
    BMC Cardiovasc Disord; 2017 Jan 06; 17(1):15. PubMed ID: 28056795
    [Abstract] [Full Text] [Related]

  • 24. Sex Differences in Dabigatran Use, Safety, And Effectiveness In a Population-Based Cohort of Patients With Atrial Fibrillation.
    Avgil Tsadok M, Jackevicius CA, Rahme E, Humphries KH, Pilote L.
    Circ Cardiovasc Qual Outcomes; 2015 Nov 06; 8(6):593-9. PubMed ID: 26508666
    [Abstract] [Full Text] [Related]

  • 25. The Comparison of Inappropriate-Low-Doses Use among 4 Direct Oral Anticoagulants in Patients with Atrial Fibrillation: From the Database of a Single-Center Registry.
    Sato T, Aizawa Y, Fuse K, Fujita S, Ikeda Y, Kitazawa H, Takahashi M, Okabe M.
    J Stroke Cerebrovasc Dis; 2018 Nov 06; 27(11):3280-3288. PubMed ID: 30121155
    [Abstract] [Full Text] [Related]

  • 26. Thromboembolic events, bleeding, and drug discontinuation in patients with atrial fibrillation on anticoagulation: a prospective hospital-based registry.
    Königsbrügge O, Simon A, Domanovits H, Pabinger I, Ay C.
    BMC Cardiovasc Disord; 2016 Dec 09; 16(1):254. PubMed ID: 27938343
    [Abstract] [Full Text] [Related]

  • 27. Risk of Thromboembolic Events in Patients with Non-Valvular Atrial Fibrillation After Dabigatran or Rivaroxaban Discontinuation - Data from the Ljubljana Registry.
    Vene N, Mavri A, Gubenšek M, Tratar G, Vižintin Cuderman T, Pohar Perme M, Blinc A.
    PLoS One; 2016 Dec 09; 11(6):e0156943. PubMed ID: 27280704
    [Abstract] [Full Text] [Related]

  • 28. Dabigatran etexilate for thromboembolic prophylaxis in non-valvular atrial fibrillation: the RE-LY study and substudies with commentary.
    Waks JW, Zimetbaum PJ.
    Expert Rev Cardiovasc Ther; 2013 Nov 09; 11(11):1461-71. PubMed ID: 24147516
    [Abstract] [Full Text] [Related]

  • 29. Dabigatran for stroke prevention in nonvalvular atrial fibrillation: focus in the geriatric population.
    Brunetti L, Chen C, White J.
    Consult Pharm; 2014 Mar 09; 29(3):169-78. PubMed ID: 24589766
    [Abstract] [Full Text] [Related]

  • 30. Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation: a prospective nationwide cohort study.
    Larsen TB, Rasmussen LH, Skjøth F, Due KM, Callréus T, Rosenzweig M, Lip GY.
    J Am Coll Cardiol; 2013 Jun 04; 61(22):2264-73. PubMed ID: 23562920
    [Abstract] [Full Text] [Related]

  • 31. [Effectiveness, safety and costs of stroke prevention in non-valvular auricular fibrillation. Study of cohorts matched by Propensity score].
    Giner-Soriano M, Casajuana M, Roso-Llorach A, Vedia C, Morros R.
    Aten Primaria; 2020 Mar 04; 52(3):176-184. PubMed ID: 31551166
    [Abstract] [Full Text] [Related]

  • 32. Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial Fibrillation.
    Renda G, Zimarino M, Ricci F, Piccini JP, Ezekowitz MD, Patel MR, Cappato R, Giugliano RP, De Caterina R.
    Am J Med; 2016 Oct 04; 129(10):1117-1123.e2. PubMed ID: 27262782
    [Abstract] [Full Text] [Related]

  • 33. A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system.
    Villines TC, Schnee J, Fraeman K, Siu K, Reynolds MW, Collins J, Schwartzman E.
    Thromb Haemost; 2015 Nov 25; 114(6):1290-8. PubMed ID: 26446456
    [Abstract] [Full Text] [Related]

  • 34. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack.
    Coleman CI, Peacock WF, Bunz TJ, Alberts MJ.
    Stroke; 2017 Aug 25; 48(8):2142-2149. PubMed ID: 28655814
    [Abstract] [Full Text] [Related]

  • 35. Dabigatran Versus Warfarin for Atrial Fibrillation in Real-World Clinical Practice: A Systematic Review and Meta-Analysis.
    Romanelli RJ, Nolting L, Dolginsky M, Kym E, Orrico KB.
    Circ Cardiovasc Qual Outcomes; 2016 Mar 25; 9(2):126-34. PubMed ID: 26812933
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Body mass index is an independent predictor of major bleeding in non-valvular atrial fibrillation patients taking dabigatran.
    Lee CH, Lin TY, Chang SH, Chen CH, Hsu YJ, Hung KC, Wen MS.
    Int J Cardiol; 2017 Feb 01; 228():771-778. PubMed ID: 27888754
    [Abstract] [Full Text] [Related]

  • 39. Effectiveness and safety of dabigatran and warfarin in real-world US patients with non-valvular atrial fibrillation: a retrospective cohort study.
    Lauffenburger JC, Farley JF, Gehi AK, Rhoney DH, Brookhart MA, Fang G.
    J Am Heart Assoc; 2015 Apr 10; 4(4):. PubMed ID: 25862791
    [Abstract] [Full Text] [Related]

  • 40. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
    Nielsen PB, Skjøth F, Søgaard M, Kjældgaard JN, Lip GY, Larsen TB.
    BMJ; 2017 Feb 10; 356():j510. PubMed ID: 28188243
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.